What is SCLC?
Small cell lung cancer accounts for approximately 13–15% of all lung cancers. It arises from neuroendocrine cells in the lung, grows extremely rapidly, and almost always occurs in current or former heavy smokers. Unlike NSCLC, SCLC does not have common targetable driver mutations like EGFR or ALK — molecular testing plays a much smaller role in treatment selection. Instead, SCLC is staged and treated primarily based on disease extent (limited-stage vs. extensive-stage) and response to prior platinum-based chemotherapy.
SCLC is initially highly sensitive to chemotherapy — response rates of 60–80% are typical with carboplatin or cisplatin plus etoposide. The problem is rapid relapse: most extensive-stage patients relapse within 6–12 months of first-line treatment, and second-line options are limited. This makes clinical trials at relapse not just an option but often the best available path. The addition of atezolizumab or durvalumab to first-line chemotherapy has modestly improved outcomes, and a new wave of DLL3-targeted therapies (tarlatamab, rovalpituzumab tesirine) and other novel agents are in active trials.
SCLC Disease Staging
SCLC uses a two-stage system based on whether disease can be encompassed in a radiation field. Most trials use this staging to define eligibility:
SCLC Trial Pathways by Treatment History
First-Line, Limited-Stage
Concurrent chemoradiation (4–6 cycles of carboplatin/etoposide with thoracic RT) remains standard. Trials are testing the addition of checkpoint inhibitors (atezolizumab, durvalumab, pembrolizumab) to chemoradiation, and exploring whether immunotherapy maintenance after chemoradiation extends remission durability in this potentially curable population.
First-Line, Extensive-Stage
Carboplatin + etoposide + atezolizumab (IMpower133) or durvalumab (CASPIAN) are both FDA-approved. Trials are testing next-generation combinations: adding tarlatamab (DLL3-targeted bispecific), novel checkpoint inhibitors, or PARP inhibitors to the chemo-immunotherapy backbone to push beyond the ~12-month median OS these regimens currently achieve.
Second-Line, Sensitive Relapse
Platinum rechallenge (carboplatin + etoposide) is standard for sensitive relapse (≥90 days from completing first-line). Lurbinectedin (Zepzelca) is FDA-approved for second-line regardless of sensitivity. Trials in sensitive relapse test novel combinations — lurbinectedin + immunotherapy, DLL3-targeted agents, and ADCs — in a population more likely to respond than resistant relapse.
Second-Line+, Resistant Relapse
The highest unmet need in SCLC. Standard options (topotecan, lurbinectedin) have modest efficacy. This is where clinical trials are most critical. Tarlatamab (Imdelltra) is FDA-approved for third-line+ as a DLL3 × CD3 bispecific T-cell engager. Trials testing rovalpituzumab tesirine (DLL3-ADC), IMAB362 (CLDN6-targeted), and novel immunotherapy combinations are actively enrolling.
Emerging Targets in SCLC Trials
Unlike NSCLC, SCLC has few established molecular targets — but several are generating significant trial activity:
SCLC FAQs
Less so than in NSCLC, but it's not irrelevant. SCLC almost never harbors the actionable driver mutations common in NSCLC (EGFR, ALK, KRAS G12C), so standard molecular testing won't open targeted therapy options the way it does for adenocarcinoma. However, NGS is increasingly useful for SCLC in two ways: first, some trials use molecular subtyping (ASCL1, NeuroD1, PARP pathway alterations) as stratification or eligibility criteria; second, confirming the absence of NSCLC driver mutations is important if there's any diagnostic ambiguity, particularly in combined small cell-large cell or atypical neuroendocrine tumors. If your oncologist hasn't ordered NGS, it's worth asking whether any active trials at your center require it.
This is one of the most important distinctions in SCLC trial eligibility. Sensitive relapse means your cancer progressed 90 or more days after you completed your last dose of first-line platinum-based chemotherapy. Resistant relapse means progression occurred within 90 days of completing chemotherapy, or your cancer never responded at all (refractory). Many trials specify which population they enroll — some only enroll sensitive relapse patients (who tend to respond better), others specifically focus on resistant/refractory patients where the unmet need is highest. When reviewing any second-line trial, check whether your relapse timing meets the eligibility definition. The 90-day cutoff is a hard threshold, not a guideline.
Tarlatamab (Imdelltra) is a bispecific T-cell engager that simultaneously binds DLL3 on SCLC cells and CD3 on T cells, bringing them together to kill the cancer cell. It received FDA approval in 2024 for extensive-stage SCLC after at least two prior lines of therapy. DLL3 is expressed in approximately 80% of SCLC tumors, which means most SCLC patients are potentially eligible without needing a specific biomarker test — though DLL3 IHC testing is used in some trials. If you have progressed after platinum-based chemotherapy and at least one other line of treatment, tarlatamab is now a standard option. Current trials are testing it earlier (first or second line) and in combinations with checkpoint inhibitors.
PCI is standard of care for limited-stage SCLC patients who achieve a complete or near-complete remission after chemoradiation — it reduces brain relapse rates substantially. For extensive-stage patients, the picture is more complicated: older trials showed a survival benefit from PCI, but a more recent Japanese trial (Takahashi et al.) showed no survival benefit when regular brain MRI surveillance was used instead. Current practice in the US varies: some centers still offer PCI for extensive-stage patients after good response to chemotherapy; others use active MRI surveillance. Several active trials are studying this question directly. If your oncologist has recommended or discussed PCI, ask whether a surveillance alternative or a trial comparing the two is available at your center.
(1) Pathology report confirming SCLC — including IHC markers (synaptophysin, chromogranin A, CD56, TTF-1) that establish neuroendocrine origin. Mixed histology (combined SCLC) should be noted. (2) Staging workup — CT chest/abdomen/pelvis and brain MRI establishing limited vs. extensive stage. (3) Complete treatment history — every prior regimen, the number of cycles, best response achieved, and the date of last chemotherapy dose (critical for calculating sensitive vs. resistant relapse). (4) Recent imaging showing current disease extent (usually within 4 weeks of enrollment). (5) ECOG performance status — most SCLC trials require ECOG 0–1; some accept ECOG 2. (6) Relevant labs including CBC, comprehensive metabolic panel, and LDH (often elevated in SCLC and used as a stratification factor).
Ready to find your matching SCLC trials?
Upload your pathology report or treatment summary. We'll confirm your stage and treatment history, match you to recruiting trials, and give you an eligibility breakdown for each one.